1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: Vaccines, Oncology Frame Q4 Contrasts Between Pfizer And GSK

The Battle Of The RSV Vaccines Is Only Part Of The Story

 
• By Andy Smith

While attempting to move beyond post-pandemic unfavorable revenue comparisons, other unfavorable comparisons emerged at Pfizer.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

Unlike Johnson & Johnson the previous week, Pfizer Inc.’s* stock price traded up by about 1% in the premarket on its fourth-quarter and full-year 2023 results announcement. This accelerated through its conference call with Pfizer’s stock price initially opening up by about 2% in normal trading. But like J&J, within a few minutes of the market open, Pfizer’s stock headed into the red and closed down by nearly 2% compared with the NYSE Arca Pharmaceutical Index’s (DRG’s) modest loss for the day.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

Stock Watch: How Tariff Threat Might Boost Pharma Q1

 
• By Andy Smith

Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.

Stock Watch: Are Gene Therapy Prices Too High For Success?

 
• By Andy Smith

The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.

Stock Watch: Bayer’s Movable Goalposts

 
• By Andy Smith

After lowering its full-year earnings guidance just six weeks before the end of 2024, Bayer, by talking up of the prospects for its new drug launches and a major clinical trial result in 2025, might risk damaging its integrity further.

Stock Watch: Hesitant Vaccine Sales For CSL Reflect Wider Issues

 
• By Andy Smith

CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.